Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Outstanding (Diluted Average) (2018 - 2024)

Catalyst Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $123.4 million for Q1 2024.

  • For Q1 2024, Shares Outstanding (Diluted Average) rose 8.26% year-over-year to $123.4 million; the TTM value through Mar 2024 reached $123.4 million, up 8.26%, while the annual FY2023 figure was $113.8 million, 2.13% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $123.4 million in Q1 2024 per CPRX's latest filing, up from $113.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $123.4 million in Q1 2024 to a low of $106.2 million in Q4 2020.
  • Average Shares Outstanding (Diluted Average) over 5 years is $110.3 million, with a median of $109.0 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): decreased 0.68% in 2020, then grew 8.26% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $106.2 million in 2020, then grew by 1.46% to $107.8 million in 2021, then grew by 3.32% to $111.4 million in 2022, then rose by 2.13% to $113.8 million in 2023, then grew by 8.48% to $123.4 million in 2024.
  • Per Business Quant, the three most recent readings for CPRX's Shares Outstanding (Diluted Average) are $123.4 million (Q1 2024), $113.8 million (Q4 2023), and $113.8 million (Q3 2023).